{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,25]],"date-time":"2026-07-25T03:22:08Z","timestamp":1784949728740,"version":"3.55.0"},"reference-count":20,"publisher":"Wiley","issue":"6","license":[{"start":{"date-parts":[[2021,1,21]],"date-time":"2021-01-21T00:00:00Z","timestamp":1611187200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["HIV Medicine"],"published-print":{"date-parts":[[2021,7]]},"abstract":"<jats:sec><jats:title>Objectives<\/jats:title><jats:p>We evaluated the virological response and resistance profile in combined antiretroviral therapy (cART)\u2010experienced HIV\u20101\u2010infected patients starting a dual therapy with dolutegravir (DTG) and boosted darunavir (bDRV) for the first time.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>Survival analyses were used to evaluate virological success (VS) and virological rebound (VR) in viraemic and virologically suppressed patients, respectively. Major resistance mutations (MRMs) and genotypic susceptibility score (GSS) were evaluated at baseline and after switch.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>Overall, 130 patients [62 (47.7%) viraemic; 68 (52.3%) virologically suppressed] were retrospectively analysed. At the moment of switch, 81.5% accumulated one or more MRM [protease inhibitor (PI), 35.7%; nucleoside(t)ide reverse transcriptase inhibitor (NRTI), 77.5%; non\u2010NRTI, 69.0%; integrase inhibitor (INI), 10.1%), but 77.7% harboured strains fully susceptible to DTG\u00a0+\u00a0bDRV. In viraemic patients, the overall probability of VS by 12\u00a0months of treatment was 91.7%. In virologically suppressed patients, the overall probability of VR was 10.5% by 24\u00a0months after therapy start. Patients with previous time under virological suppression\u00a0\u2264\u00a06\u00a0months showed a higher VR probability compared with others (37.5% <jats:italic>vs<\/jats:italic>. 6.7%, <jats:italic>P<\/jats:italic>\u00a0&lt;\u00a00.002). Among 13 non\u2010responding patients for whom a genotypic resistance test result at failure was available, only two (15.4%) accumulated further resistance in integrase (Y143C\/H\/R; S147G and N155H) and protease (V32I, L33F, I54L).<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusions<\/jats:title><jats:p>In highly treatment\u2010experienced patients, the use of dual therapy based on DTG\u00a0+\u00a0bDRV appears to be a very good regimen for switch therapy, with a high rate of virological control in both viraemic and virologically suppressed patients. Among non\u2010responding patients, the selection of further resistance is a rare event.<\/jats:p><\/jats:sec>","DOI":"10.1111\/hiv.13062","type":"journal-article","created":{"date-parts":[[2021,1,22]],"date-time":"2021-01-22T07:54:15Z","timestamp":1611302055000},"page":"519-525","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":9,"title":["Virological response and resistance profile in highly treatment\u2010experienced HIV\u20101\u2010infected patients switching to dolutegravir plus boosted darunavir in clinical practice"],"prefix":"10.1111","volume":"22","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-3406-7014","authenticated-orcid":false,"given":"Daniele","family":"Armenia","sequence":"first","affiliation":[{"name":"Saint Camillus International University of Health Sciences Rome Italy"},{"name":"Department of Experimental Medicine University of Rome \u201cTor Vergata\u201d Rome Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yagai","family":"Bouba","sequence":"additional","affiliation":[{"name":"Department of Experimental Medicine University of Rome \u201cTor Vergata\u201d Rome Italy"},{"name":"Chantal BIYA International Reference Centre for research on HIV\/AIDS prevention and management (CIRCB) Yaound\u00e9 Cameroon"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Roberta","family":"Gagliardini","sequence":"additional","affiliation":[{"name":"HIV\/AIDS Department IRCCS National Institute for Infectious Diseases \u201cLazzaro Spallanzani\u201d Rome Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lavinia","family":"Fabeni","sequence":"additional","affiliation":[{"name":"Laboratory of Virology IRCCS National Institute for Infectious Diseases \u201cLazzaro Spallanzani\u201d Rome Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vanni","family":"Borghi","sequence":"additional","affiliation":[{"name":"Clinic of Infectious Diseases Modena University Hospital University of Modena and Reggio Emilia Modena Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giulia","family":"Berno","sequence":"additional","affiliation":[{"name":"Laboratory of Virology IRCCS National Institute for Infectious Diseases \u201cLazzaro Spallanzani\u201d Rome Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6944-0686","authenticated-orcid":false,"given":"Alessandra","family":"Vergori","sequence":"additional","affiliation":[{"name":"HIV\/AIDS Department IRCCS National Institute for Infectious Diseases \u201cLazzaro Spallanzani\u201d Rome Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stefania","family":"Cicalini","sequence":"additional","affiliation":[{"name":"HIV\/AIDS Department IRCCS National Institute for Infectious Diseases \u201cLazzaro Spallanzani\u201d Rome Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cristina","family":"Mussini","sequence":"additional","affiliation":[{"name":"Clinic of Infectious Diseases Modena University Hospital University of Modena and Reggio Emilia Modena Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrea","family":"Antinori","sequence":"additional","affiliation":[{"name":"HIV\/AIDS Department IRCCS National Institute for Infectious Diseases \u201cLazzaro Spallanzani\u201d Rome Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francesca","family":"Ceccherini\u2010Silberstein","sequence":"additional","affiliation":[{"name":"Department of Experimental Medicine University of Rome \u201cTor Vergata\u201d Rome Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carlo Federico","family":"Perno","sequence":"additional","affiliation":[{"name":"Laboratory of Virology IRCCS National Institute for Infectious Diseases \u201cLazzaro Spallanzani\u201d Rome Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6228-1114","authenticated-orcid":false,"given":"Maria Mercedes","family":"Santoro","sequence":"additional","affiliation":[{"name":"Department of Experimental Medicine University of Rome \u201cTor Vergata\u201d Rome Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2021,1,21]]},"reference":[{"key":"e_1_2_7_2_1","doi-asserted-by":"publisher","DOI":"10.1080\/14740338.2017.1343300"},{"key":"e_1_2_7_3_1","doi-asserted-by":"publisher","DOI":"10.2147\/DDDT.S140767"},{"key":"e_1_2_7_4_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jgar.2019.08.010"},{"key":"e_1_2_7_5_1","unstructured":"Panel on Antiretroviral Guidelines for Adults and Adolescents.Guidelines for the Use of Antiretroviral Agents in Adults and Adolescents with HIV. Department of Health and Human Services. Available athttp:\/\/www.aidsinfo.nih.gov\/ContentFiles\/AdultandAdolescentGL.pdf."},{"key":"e_1_2_7_6_1","doi-asserted-by":"crossref","first-page":"2112","DOI":"10.1093\/cid\/cix734","article-title":"Dual therapy with darunavir and ritonavir plus lamivudine vs triple therapy with darunavir and ritonavir plus tenofovir disoproxil fumarate and emtricitabine or abacavir and lamivudine for maintenance of human immunodeficiency virus Type 1 Viral Suppression","volume":"65","author":"Pulido F","year":"2017","journal-title":"Clin Infect Dis"},{"key":"e_1_2_7_7_1","doi-asserted-by":"publisher","DOI":"10.1016\/S2352-3018(19)30149-3"},{"key":"e_1_2_7_8_1","doi-asserted-by":"publisher","DOI":"10.1093\/cid\/ciz1243"},{"key":"e_1_2_7_9_1","doi-asserted-by":"publisher","DOI":"10.1093\/jac\/dkaa018"},{"key":"e_1_2_7_10_1","doi-asserted-by":"publisher","DOI":"10.1093\/jac\/dky467"},{"key":"e_1_2_7_11_1","unstructured":"European AIDS Clinical Society (EACS).Guidelines version 10.0. November 2019. Available at:https:\/\/www.eacsociety.org\/files\/2019_guidelines\u201010.0_final.pdf."},{"key":"e_1_2_7_12_1","doi-asserted-by":"publisher","DOI":"10.1093\/ofid\/ofaa356"},{"key":"e_1_2_7_13_1","doi-asserted-by":"publisher","DOI":"10.1186\/s12879-017-2755-4"},{"key":"e_1_2_7_14_1","doi-asserted-by":"publisher","DOI":"10.3947\/ic.2018.50.3.252"},{"key":"e_1_2_7_15_1","doi-asserted-by":"publisher","DOI":"10.1080\/15284336.2018.1550290"},{"key":"e_1_2_7_16_1","doi-asserted-by":"publisher","DOI":"10.3851\/IMP3330"},{"key":"e_1_2_7_17_1","doi-asserted-by":"publisher","DOI":"10.3851\/IMP3319"},{"key":"e_1_2_7_18_1","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0210476"},{"key":"e_1_2_7_19_1","doi-asserted-by":"publisher","DOI":"10.1002\/phar.2227"},{"key":"e_1_2_7_20_1","doi-asserted-by":"publisher","DOI":"10.1093\/cid\/ciu020"},{"key":"e_1_2_7_21_1","doi-asserted-by":"crossref","first-page":"1865","DOI":"10.1093\/jac\/dkv029","article-title":"HIV\u20101 integrase genotyping is reliable and reproducible for routine clinical detection of integrase resistance mutations even in patients with low\u2010level viraemia","volume":"70","author":"Armenia D","year":"2014","journal-title":"J Antimicrob Chemother"}],"container-title":["HIV Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/hiv.13062","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full-xml\/10.1111\/hiv.13062","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/hiv.13062","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,8,30]],"date-time":"2023-08-30T12:35:37Z","timestamp":1693398937000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/hiv.13062"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,1,21]]},"references-count":20,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2021,7]]}},"alternative-id":["10.1111\/hiv.13062"],"URL":"https:\/\/doi.org\/10.1111\/hiv.13062","archive":["Portico"],"relation":{},"ISSN":["1464-2662","1468-1293"],"issn-type":[{"value":"1464-2662","type":"print"},{"value":"1468-1293","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,1,21]]},"assertion":[{"value":"2020-10-09","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2020-12-12","order":1,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2021-01-21","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}